Prospects for the Management of Non-Small-Cell Carcinoma of the Lung with Monoclonal Antibodies: Applications (5)

The upper image is a transaxial emission tomogram taken 72 h postinjection of a therapeutic dose of 10.28 mg of anti-CEA F(ab’)2 labeled with 88.6 mCi of1. The upper image shows two lesions in the right lung denoted by arrows. The lower image is a transaxial computed tomography image showing the left thoracotomy and the two corresponding lesions in the right lung. Cheap Diskus AdvairTherapy Studies
Although no tumor-associated antigens have been shown to be present exclusively on neoplastic cells in NSCCL, antigens that are expressed at significantly higher levels in neoplastic cells than in normal cells may be suitable targets for MAb-directed therapy. MAbs are being exploited from several perspectives in the area of cancer therapy, including the use of MAbs as vehicles for site-directed delivery of drugs or radioisotopes, and the exploitation of host immune mechanisms for antibody-dependent cellular cytotoxicity and complement-mediated toxicity. The MAbs KM-32 and KM-34, and L6, have shown complement-dependent cytotoxicity against lung tumor cell lines. In addition, MAbs L6 and MBA9812-16B-13 mediate ADCC in the presence of human lymphocytes [>r mouse macrophages as effector cells, respectively, and can suppress the growth of antigen-positive human carcinomas in nude mice.